​

ZyVersa Therapeutics Stock (NASDAQ:ZVSA)

OwnershipFinancialsChart
ZyVersa Therapeutics by TradingView

Previous Close

$0.18

52W Range

$0.11 - $1.67

50D Avg

$0.19

200D Avg

$0.18

Market Cap

$1.30M

Avg Vol (3M)

$10.09K

Beta

0.81

Div Yield

-

ZVSA Company Profile

ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Feb 11, 2022

Website

ZVSA Performance

ZVSA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-25.49B$-9.14B$-14.42M
Net Income$-24.95B$-9.41B$-98.30M
EBITDA$-25.49B$-9.14B$-107.74M
Basic EPS$-4.18$-8.48$-1.09K
Diluted EPS$-4.18$-8.48$-1.09K

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
XAGELongevity Health Holdings Inc.
WORXSCWorx Corp.
JSPRJasper Therapeutics, Inc.
CDTCDT Equity Inc.
ONCOOnconetix, Inc.
SLXNSilexion Therapeutics Ltd.
INDPIndaptus Therapeutics, Inc.
NIVFNewGenIvf Group Limited
ENVBEnveric Biosciences, Inc.